Opko Health (OPK) – Analysts’ Weekly Ratings Updates

A number of research firms have changed their ratings and price targets for Opko Health (NASDAQ: OPK):

  • 2/9/2018 – Opko Health was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies. “
  • 2/3/2018 – Opko Health was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies. “
  • 2/2/2018 – Opko Health was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 1/26/2018 – Opko Health was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 1/24/2018 – Opko Health was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies. “
  • 1/11/2018 – Opko Health was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies. “
  • 1/10/2018 – Opko Health was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.

Opko Health Inc. (NASDAQ OPK) traded down $0.05 during trading on Wednesday, hitting $3.90. The company had a trading volume of 3,481,100 shares, compared to its average volume of 4,769,566. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.66 and a quick ratio of 1.48. Opko Health Inc. has a 12-month low of $3.61 and a 12-month high of $8.92. The firm has a market capitalization of $2,209.65, a P/E ratio of -17.73 and a beta of 1.42.

In related news, CEO Phillip Md Et Al Frost purchased 185,000 shares of Opko Health stock in a transaction that occurred on Friday, February 9th. The stock was bought at an average cost of $3.83 per share, for a total transaction of $708,550.00. Following the completion of the transaction, the chief executive officer now owns 3,068,951 shares in the company, valued at $11,754,082.33. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have purchased 688,000 shares of company stock valued at $2,970,260 in the last ninety days. Corporate insiders own 40.19% of the company’s stock.

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Receive News & Ratings for Opko Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply